# MR Antagonist and LSD1

Study · id `cardio:ct-nct04840342` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04840342](<https://clinicaltrials.gov/study/NCT04840342>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04840342

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

## Technical summary

Registry record NCT04840342. Randomized; triple masking; primary purpose treatment. Start 2022-02-03 (actual); primary completion 2025-09-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT04840342, source copy `cardio:ctgov-nct04840342-2026-10-01`, retrieved 2026-10-26)
- Started: 2022-02-03 (actual) (ClinicalTrials.gov record NCT04840342, source copy `cardio:ctgov-nct04840342-2026-10-01`, retrieved 2026-10-26)
- Primary completion: 2025-09-15 (actual) (ClinicalTrials.gov record NCT04840342, source copy `cardio:ctgov-nct04840342-2026-10-01`, retrieved 2026-10-26)
- Completion: 2025-12-15 (actual) (ClinicalTrials.gov record NCT04840342, source copy `cardio:ctgov-nct04840342-2026-10-01`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04840342, source copy `cardio:ctgov-nct04840342-2026-10-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04840342-2026-10-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: MR Antagonist and LSD1
- Condition: Hypertension
- Condition: Mineralocorticoid Excess
- Intervention (Drug): Eplerenone
- Intervention (Drug): Amlodipine
- Lead sponsor: Brigham and Women's Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)
- Registry lists this organization as the lead sponsor: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)

## Provenance

Content hash: d7d4ea2ffd234bb56c92e211b440baab726a873574db4f0a03bb1edf7ea51382
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
